 |
 Video: What is a Stock Split?
|
|
|
| Caribou Biosciences is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats genome-editing biopharmaceutical company focused on developing therapies for patients with devastating diseases. Co.'s CB-010 is a clinical-stage allogeneic anti-CD19 chimeric antigen receptor (CAR)-T (CAR-T) cell therapy with programmed cell death protein 1 removed from the CAR-T cell surface by a genome-edited knockout of the PDCDI gene. Co.'s CB-011 is an allogeneic CAR-T cell therapy that is an anti-B cell maturation antigen CAR-T cell therapy incorporating an immune cloaking approach. Co.'s CB-012 is an allogeneic CAR-T cell therapy targeting C-type lectin-like molecule-1. According to our Caribou Biosciences stock split history records, Caribou Biosciences has had 0 splits. | |
|
Caribou Biosciences (CRBU) has 0 splits in our Caribou Biosciences stock split history database.
Looking at the Caribou Biosciences stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Caribou Biosciences shares, starting with a $10,000 purchase of CRBU, presented on a split-history-adjusted basis factoring in the complete Caribou Biosciences stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
07/26/2021 |
|
| End date: |
04/26/2024 |
|
| Start price/share: |
$16.75 |
|
| End price/share: |
$3.71 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-77.85% |
|
| Average Annual Total Return: |
-42.16% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$2,214.69 |
|
| Years: |
2.75 |
|
|
|
|
|
